Nanotechnology uses biocompatible/biodegradable polymers and lipids to encapsulate the drug within nanometer sized carrier molecules.

Most cancer treatments involve the use of drugs that are toxic, since these reach both normal and cancer cells, and may cause side effects. By improving drug delivery to cancer cells it is possible to minimise side effects.

Nanoparticle technology with < 200 nm mean size uses GRAS materials with a long history of use in the manufacture of injectable pharmaceuticals. The product that is presently available in the market contains excipients in high quantities- this can cause toxicity and hypersensitivity or they may contain protein that may become immunogenic due to the harsh process used in their manufacturing. Our product is not likely to have such properties. The product has improved safety index as tested in mice. Our technology is at preclinical development stage with demonstrated proof of concept.

When phospholipids are dispersed in an aqueous medium, they swell, hydrate and form bi-layer vesicles with layers of aqueous media separating the lipid bylayers. Such liposomes are completely inert, biodegradable, and can be used to entrap a large number of drugs which are then protected from enzymatic degradation or inactivation. Since these are large, liposomes can exit only where large pores exist in the capillary endothelia. They can reach the blood, liver, spleen, bone marrow and lymphoid organs. Liposomes can also accumulate in leaky vasculature of solid tumours. Active targeting with drug entrapped liposomes can be achieved by attaching ligands to the carrier systems.

Cytotoxic drugs have severe organ toxicity such as cardiotoxicity, but by encapsulation into liposomes, the drug distribution to the heart is reduced, leading to minimal toxicity.

Our process offers over 98% encapsulation of the medication, and in doing so, removes non-encapsulated drug and other undesirable excipients. Our process can be used on a commercial scale with high reproducibility across batches.

This nanoparticle platform technology is at preclinical development stage, with demonstrated proof of concept. Two cytotoxic products are being developed based on this technology.